A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs.

By M. Peet, D. Horrobin. Archives of General Psychiatry, 2002

626 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Beneficial Outcomes of Omega-6 and Omega-3 Polyunsaturated Fatty Acids on Human Health: An Update for 2021 (2021, background): “The first trial of omega-3 PUFAs in schizophrenia 405 identified clinical improvement with EPA (2 g/day), but not with DHA [113], while sub- 406 sequent trials also showed benefit with EPA [114,115], but not all studies have seen this 407 [116].”
Marine Bioactives as Functional Food Ingredients: Potential to Reduce the Incidence of Chronic Diseases (2011, background): “In some trials, supplementation with long chain n-3 PUFAs has been shown to improve mood in patients with major depression and bipolar disorder [271–274].”
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines (2015, background): “There is some evidence for the use of EPA or EPA+DHA/fish oil as adjunctive treatment in three RCTs in depression not responding to antidepressants (Nemets et al., 2002; Peet and Horrobin, 2002; Su et al., 2003).”
Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. (2006, background): “This observation raises the possibility that omega-3 EFA have a “ceiling,” or maximally effective dose.(62) A”